Heartflow, Inc. enrolled its first patient in the NAVIGATE‑PCI Registry, a large‑scale study designed to evaluate the real‑world impact of its PCI Navigator AI platform on percutaneous coronary intervention (PCI) planning, procedural efficiency, and physician confidence.
The registry will track how often treatment plans change when interventional cardiologists use Heartflow’s AI‑driven insights—detailing coronary anatomy, plaque composition, and lesion‑specific physiology—compared with traditional angiography alone. The study aims to demonstrate that pre‑procedural AI analysis can improve procedural strategy and outcomes for patients undergoing PCI.
Heartflow’s CEO and Chief Medical Officer emphasized that the launch of the NAVIGATE‑PCI Registry is a key step in building the evidence base needed to support AI‑driven decision making across the entire coronary artery disease care continuum, from risk stratification to intervention planning. The data generated will help validate the platform’s effectiveness and support broader adoption and payer acceptance.
The PCI Navigator is expected to become commercially available in the second quarter of 2026, and the registry will enroll 5,000 patients to generate robust real‑world evidence. This evidence base will strengthen Heartflow’s market position in the rapidly evolving cardiovascular AI space and provide a competitive advantage over other AI‑based diagnostic and planning tools.
Analysts and institutional investors remain constructive on Heartflow, and the successful completion of the registry could accelerate adoption of the PCI Navigator, enhance the company’s competitive positioning, and potentially influence payer coverage and reimbursement for AI‑driven coronary artery disease management.
The launch of the NAVIGATE‑PCI Registry marks a significant milestone in Heartflow’s mission to transform coronary artery disease management through AI, positioning the company to deliver more precise, data‑driven PCI planning and improve patient outcomes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.